CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,808 enrolled
Drug / intervention
BAY2433334 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04304508
NCT04304508Phase 2Completed
CompareCT.gov

Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate Efficacy and Safety of BAY2433334 in Patients Following an Acute Non-cardioembolic Ischemic Stroke

Bayer·interventional·Posted Mar 11, 2020·Updated Apr 19, 2023

In Brief

A Phase 2 clinical trial evaluating BAY2433334 and BAY2433334 matching placebo for Acute Non-cardioembolic Ischemic Stroke. Completed, enrolled 1,808 participants across 197 sites in 23 countries.

Detailed Summary

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Non-cardioembolic Ischemic Stroke
CountriesAustralia, Austria, Belgium, Bulgaria, China, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, United Kingdom, United States
CollaboratorsPopulation Health Research Institute

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 11, 2020
Enrollment StartJun 15, 2020
Primary CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.3 years ago

Interventions

BAY2433334drug

Tablet, taken orally once a day.

BAY2433334 matching placeboother

Tablet, taken orally once a day.